AALL1521: INCB 18424-269 A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia (ALL)

Brief description of study

If you are the parent or guardian of a child/adolescent diagnosed with acute lymphoblastic leukemia, your child may qualify to participate in a clinical trial investigating ruxolitinib and combination chemotherapy.  The main goals of this study is to evaluate the safety and tolerability of ruxolitinib in combination with chemotherapy and to see how well they work in children and adolescents and young adults (AYA) with high risk Philadelphia chromosome-like (Ph-like) CRLF2-R and/or JAK pathway-mutant B-ALL.

Clinical Study Identifier: s16-01159
ClinicalTrials.gov Identifier: NCT02723994
Principal Investigator: Sharon L Gardner.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.